CLINICAL TRIALS
Biomobie Technology
[Report for Studies on the Health Benefits of Pulsed Electromagnetic Field Therapy using Bioboosti]

Biomobie Partner Mayo Clinic Breakthrough in Study of Microcirculation in Heart Disease and Aging

 

High-tech medical interventions have been increasingly important in cutting edge solutions to age-old problems and chronic diseases related to aging. A recent study at the Mayo Clinic revealed that Biomobie’s Pulsed Electro-Magnetic Field (PEMF) therapy has been demonstrated to increase microcirculation which in turn appears to rebuild and normalize the circulatory system reversing the effects of chronic diseases among the aging population.

 

Health Problems Related to Aging

According to the World Health Organization (WHO) in 2010, an estimated 524 million people were aged 65 or older—8% of the world’s population. By 2050, this number is expected to nearly triple to about 1.5 billion, representing 16% of the world’s population. One of the major epidemiologic trends of the current century is the rise of chronic and degenerative diseases in countries throughout the world as the population ages in numbers humans have never seen before. Over the next 10 to 15 years, people in every world region will suffer more death and disability from such chronic diseases as heart disease, cancer, and diabetes than from infectious diseases.

 

Microcirculation Key to Normalizing Circulation

Scientists at the Mayo Clinic say that the first part of the body’s vital function that tends to degenerate with age is the microcirculatory system. While circulation refers to blood flow to and from vital organs, microcirculation refers to blood flow in the smallest blood vessels in the body – capillaries, arterioles, and other such blood vessels. These blood vessels are often embedded in the organs, including the skin, and interact directly with muscle tissue. Impaired microcirculatory problems have been shown to occur in certain chronic disease states including peripheral vascular disease, diabetes, high cholesterol, high blood pressure, chronic renal failure, and venous insufficiency, as well as in menopause, advanced age, and obesity. Poor microcirculation is one of the single biggest contributing factors to almost all health problems: diabetes, hypertension, vascular disease, atherosclerosis, kidney disease, Alzheimer’s, early aging and others. It is estimated that 80% of the population over the age of 40 may have moderately to extremely serious microcirculation problems.

Microcirculation appears to have an effect on a wide range of health problems that we call “chronic diseases.” Noncommunicable - or chronic diseases are diseases of long duration and generally slow progression. The four main types of noncommunicable diseases are cardiovascular diseases (like heart attacks and stroke), cancer, chronic respiratory diseases (such as chronic obstructed pulmonary disease and asthma) and diabetes. Chronic diseases are responsible for 7 of 10 deaths each year and treating people with chronic diseases accounts for most of our nation’s health care costs. 1 in 2 adults in America has chronic disease. 1 in 4 have 2 chronic diseases. These chronic diseases are by far the leading cause of death in the world, representing 63% of all annual deaths. Noncommunicable diseases (NCDs) kill more than 36 million people each year.

With this in mind, researchers at the world-famous Mayo Clinic conducted a clinical trial using Biomobie’s “Bioboosti,” a handheld device that emits a pulsed electro-magnetic field (PEMF), in order to test the efficacy of the device to enhance microcirculation. What they discovered is that daily “Bioboosti” therapy does aid in normalizing microcirculation in individual and in case studies. Biomobie is currently working in collaboration with the Mayo Clinic in order to determine what connections there may be between improved microcirculation and the use of Bioboosti.

 

If microcirculation is so critical to all bodily functions including the heart, brain, and all organ functioning, what is the connection between microcirculation and chronic diseases which affect all these critical organs? These two things, microcirculation and chronic diseases have been shown to be closely related, especially in the elderly population. What can medical researchers discover as the link connecting these things? What is the cause of the dysfunction of microcirculation? This is an area of critical concern in an era of such massive chronic diseases, with further research needing to be done.

 

The Biomobie technological breakthrough promises to be the third most effective new treatment to curb the "epidemic" of chronic diseases after medicine and vaccines, quietly repeating the history of smallpox conquest.

梅奥诊所在改善心脏微循环的临床研究取得重大突破

 

在老龄化问题和老龄化相关慢性疾病的前沿解决方案中,高科技医疗干预的作用越来越重要。梅奥诊所最新研究显示,百慕迪的bioboosti技术通过改善微循环,转而重建循环系统,治疗慢性疾病。继药物和疫苗后,预防和控制慢性疾病的最有效的新疗法,悄然重复着牛痘治愈天花的历史。

 

老龄化有关的健康问题

根据世界卫生组织(WHO)2010 年的统计,65 岁或以上人口约有 5.24 亿人 - 占世界总人口的 8%。到 2050 年,这一数字预计将增至近 3 倍,约 15 亿,占全球总人口的 16%。本世纪的主要流行病学趋势之一是世界各国的慢性和退行性疾病的增加,这一趋势与老龄化人口数量的大量增长都是前所未有的。在接下来的 10 至 15 年间,慢性疾病如心脏病、脑卒中、高血压和糖尿病等导致的死亡率和致残率将远高于传染性疾病。

 

循环系统正常化的关键 -- 微循环正常化

梅奥诊所科学家认为,首先随年龄增长而退化的机体重要功能是微循环系统功能。血液循环是指血液在血管内循环往复流动,而微循环则是指微动脉和微静脉之间的血液循环。这些微血管在机体内无处不在,为各个组织器官供血供氧。微循环障碍是造成几乎所有健康问题的最主要因素之一,如糖尿病、高血压、血管疾病、高胆固醇、肾脏疾病、阿尔茨海默病、早衰、肥胖症等。据估计,40 岁以上人群中有 80%可能有中重度微循环障碍。微循环似乎对慢性疾病都能产生一定的影响。 慢性疾病是指持续时间长,病情进展缓慢的疾病。主要有以下四种类型:心血管疾病(如心脏病和中风)、癌症、慢性呼吸系统疾病(如慢性阻塞性肺病和哮喘)和糖尿病。 慢性病患者死亡人数占美国总死亡人数的 70%以上,其治疗费用占美国国家医疗保健成本的大部分。 美国成年人中有 1/2 患有一种慢性病,1/4 同时患有两种慢性病。而这些慢性病是迄今为止世界上人口死亡的主要原因,占全年死亡人数的 63%,慢性疾病每年造成超过 3600 万人死亡。 微循环对各个组织器官的机能如此重要,且微循环和慢性病密切相关,尤其在老年人口中。那么微循环与慢性疾病之间的关联是什么?微循环障碍的原因是什么?在当今慢性病盛行的时代,这都需要密切关注,并深入研究。

基于此,梅奥诊所研究人员的试验结果显示,Bioboosti 可以改善微循环,使受损微循环逐渐正常化,从而改善多种慢性疾病。

Mayo Clinic
Biomobie 全部产品细节都已经过国家专利版权保护
未经授权不得以任何方式盗用或模仿
违者必究
Biomobie all product details have been over the nationanl patent copyright protection Without authorization
shall not be used in any way to steal or imitate
Those who violate the law will be subject to legal sanctions

Biomobie (shanghai) Regenerative Medicine co., Ltd.

扫描二维码分享到微信